(NASDAQ: VERV) Verve Therapeutics's forecast annual revenue growth rate of -32.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.72%.
Verve Therapeutics's revenue in 2025 is $59,613,000.On average, 4 Wall Street analysts forecast VERV's revenue for 2025 to be $3,769,867,493, with the lowest VERV revenue forecast at $1,096,461,815, and the highest VERV revenue forecast at $6,436,141,711. On average, 3 Wall Street analysts forecast VERV's revenue for 2026 to be $2,650,495,866, with the lowest VERV revenue forecast at $1,096,461,815, and the highest VERV revenue forecast at $4,662,191,295.
In 2027, VERV is forecast to generate $1,644,692,723 in revenue, with the lowest revenue forecast at $1,096,461,815 and the highest revenue forecast at $2,192,923,630.